Weiss Ratings Reaffirms "Sell (D-)" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

FDMT has been the topic of a number of other research reports. The Goldman Sachs Group lowered their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Chardan Capital reiterated a "buy" rating and set a $25.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, July 3rd. Finally, Barclays lowered their target price on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $29.56.

4D Molecular Therapeutics Stock Performance

NASDAQ FDMT traded up $0.10 during trading hours on Friday, hitting $4.36. 275,862 shares of the company traded hands, compared to its average volume of 778,754. The business's 50-day moving average is $3.94 and its 200-day moving average is $4.12. 4D Molecular Therapeutics has a twelve month low of $2.24 and a twelve month high of $19.69. The stock has a market capitalization of $202.00 million, a price-to-earnings ratio of -1.37 and a beta of 2.81.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 767,126.06% and a negative return on equity of 33.26%. Analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds have recently added to or reduced their stakes in FDMT. BVF Inc. IL increased its stake in 4D Molecular Therapeutics by 70.8% during the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock worth $14,733,000 after acquiring an additional 1,890,647 shares during the period. Millennium Management LLC increased its stake in 4D Molecular Therapeutics by 1,607.1% during the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock worth $7,913,000 after acquiring an additional 1,337,497 shares during the period. Federated Hermes Inc. increased its stake in 4D Molecular Therapeutics by 33,131.8% during the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock worth $4,038,000 after acquiring an additional 1,246,419 shares during the period. JPMorgan Chase & Co. increased its stake in 4D Molecular Therapeutics by 159.5% during the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock worth $4,568,000 after acquiring an additional 504,086 shares during the period. Finally, Norges Bank bought a new position in 4D Molecular Therapeutics during the 4th quarter worth $2,790,000. Institutional investors own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.